Pharma BD Deal Intelligence
An AI-powered drug discovery collaboration where SK Biopharmaceuticals pays Insilico Medicine roughly $18M upfront against up to $2.5B in milestones plus royalties for neuroimmune CNS disorder candidates from Insilico's generative AI platform. It's Insilico's largest APAC partnership by potential value, though the deal leans almost entirely on unproven biobucks with a token upfront.
Back-loaded AI-discovery collaboration in hard-to-drug neuroimmune CNS
Full analysis, sources & comparables →SK Biopharmaceuticals and Insilico Medicine formed an AI-powered drug discovery collaboration, announced at the BIO 2026 International Convention, to discover novel candidates for neuroimmune CNS disorders using Insilico's generative AI platform. Insilico receives ~$18M in near-term payments and is eligible for up to $2.5 billion in milestones plus single-digit royalties; SK Biopharmaceuticals leads subsequent development and commercialization. It is Insilico's largest APAC partnership by potential value.
Announced at BIO 2026, SK Biopharmaceuticals and Insilico Medicine formed an AI-powered drug-discovery collaboration to discover novel candidates for neuroimmune CNS disorders (neuroinflammatory, neurodegenerative and rare neurological diseases). Insilico applies its Pharma.AI platform (target validation, generative chemistry, molecule optimization); SK Biopharmaceuticals leads late-stage development and commercialization. Insilico is eligible for up to ~$18M in upfront and near-term payments with total potential value exceeding $2.5B in development/regulatory/commercial milestones plus single-digit royalties — a heavily back-loaded, discovery-stage deal with no named clinical molecules yet.
SK Biopharmaceuticals and Insilico Medicine launch an AI-powered discovery collaboration for neuroimmune CNS disorders; ~$18M upfront/near-term, total potential >$2.5B + single-digit royalties.
Committed value is small (~$18M); the $2.5B headline is almost entirely milestone-weighted and contingent on AI-discovered programs reaching the clinic and commercialization.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| SK Biopharmaceuticals Co., Ltd. / Insilico Medicine Inc. (this deal) | 2026 | $2.5B | 48 |
| SK Biopharmaceuticals Co., Ltd. / 1ST Biotherapeutics, Inc. | 2026 | $315M | — |
| SK Biopharmaceuticals Co., Ltd. / Biohaven Pharmaceutical Holding Company Ltd. | 2026 | $795M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
← Browse all deals · How we score deals
More: 2026 deals · SK Biopharmaceuticals Co., Ltd. deals · Immunology deals